{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.01","value":"0.52"},{"groupId":"OG001","spread":"24.10","value":"-3.75"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"209"},{"groupId":"OG001","value":"91"}],"units":"Participants"}],"title":"Cycle 2, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.97","value":"2.67"},{"groupId":"OG001","spread":"21.08","value":"-2.36"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"175"},{"groupId":"OG001","value":"53"}],"units":"Participants"}],"title":"Cycle 3, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.62","value":"0.80"},{"groupId":"OG001","spread":"22.42","value":"-3.03"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"33"}],"units":"Participants"}],"title":"Cycle 4, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.81","value":"0.51"},{"groupId":"OG001","spread":"27.44","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"130"},{"groupId":"OG001","value":"27"}],"units":"Participants"}],"title":"Cycle 5 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.57","value":"-2.51"},{"groupId":"OG001","spread":"17.59","value":"-0.93"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"Cycle 6, Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"289"},{"groupId":"OG001","value":"144"}],"units":"Participants"}],"description":"The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Global Health Status/QOL scale is scored between 0 and 100, with a high score indicating better Global Health Status/QOL. Negative change from Baseline values indicate deterioration in QOL or functioning and positive values indicate improvement.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received 4 mg pomalidomide administered by mouth on Days 1-21 of each 28-day treatment cycle and 40 mg dexamethasone (participants \\> 75 years of age received 20 mg dexamethasone) administered by mouth once per day on Days 1, 8, 15, and 22 of a 28-day cycle until disease progression.","id":"OG000","title":"Pomalidomide Plus Low-Dose Dexamethasone"},{"description":"Participants received 40 mg dexamethasone (participants \\> 75 years of age received 20 mg dexamethasone) administered by mouth once per day on Days 1 through 4, 9 through 12, and 17 through 20 of a 28-day cycle until disease progression.","id":"OG001","title":"High-Dose Dexamethasone"}],"paramType":"MEAN","populationDescription":"The Patient Reported Outcomes (PRO) study population includes any intent-to-treat study participants with 1 active treatment and 1 PRO measurement item completed. Only participants with available data at Baseline and each time point are included.","reportingStatus":"POSTED","timeFrame":"Day 1 of Cycle 1 (Baseline), and Day 1 of Cycles 2, 3, 4, 5 and 6","title":"Change From Baseline in the European Organization for Research and Treatment of Cancer Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Global Health Status Domain","type":"SECONDARY","unitOfMeasure":"units on a scale"}